Hematology News

Infants who were born prematurely, had a low birth weight, experienced sepsis or underwent invasive procedures appeared to be at increased risk for thrombosis, according to study results published in Journal of Thrombosis and Haemostasis.

John P. Chute, MD, has been appointed director of the division of hematology and cellular therapy in the department of medicine at Cedars-Sinai Cancer.

Patients hospitalized with COVID-19 who received high-dose therapeutic anticoagulation appeared to be at increased risk for mortality compared with those on prophylactic anticoagulation, according to a research letter in Thrombosis Research.

As they collaborated on a study — presented at the virtual ASH Annual Meeting and Exposition — of blood types and COVID-19 severity, Shivi Jain, MD, found herself emphasizing one noteworthy detail about her co-author, Shivani Rao.

ASH recognized three Choosing Wisely Champions during the ASH Annual Meeting and Exposition.

The FDA has approved or granted special designations to several oncology or hematology agents over the past 2 weeks.

This year’s virtual ASH Annual Meeting and Exposition featured hundreds of abstracts that spotlighted research advances in blood cancer and benign hematology research.

The FDA granted breakthrough therapy designation to iptacopan for treatment of paroxysmal nocturnal hemoglobinuria.

The gene therapy etranacogene dezaparvovec conferred a substantial decrease in bleeding events among patients with moderate or severe hemophilia B, according to preliminary data presented at the virtual ASH Annual Meeting and Exposition.

The addition of mycophenolate to standard first-line steroid treatment appeared effective for patients with newly diagnosed immune thrombocytopenia, according to study results presented at the virtual ASH Annual Meeting and Exposition.